Liraglutide
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
In January 2010, liraglutide (Victoza; Novo Nordisk)--an injectable glucagon-like peptide 1 receptor agonist--was approved by the US FDA to improve glycaemic control in adults with type 2 diabetes mellitus.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The elimination half-life of liraglutide is 13 h, and only one injection per day is required.62”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [62]
Citations
Cites
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Self-citationGarber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848
on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
Marre, M., Shaw, J., Brändle, M., Bebakar, W. M. W., Kamaruddin, N. A., Strand, J., Zdravkovic, M., Le Thi, T. D., Colagiuri, S., & on behalf of the LEAD‐1 SU study group (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02666.x · Cited by 820
Knudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M., & Agersø, H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909645 · Cited by 700
Incretin-based therapies for type 2 diabetes mellitus
Lovshin, J. A., & Drucker, D. J. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.48 · Cited by 649
Self-citation
Research works printed but not linked: 2
- Knudsen, L. B. et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 4 Mar 2010 (doi: 10.1210/en.2009–1272) · DOI · Paper page
- Vosser, R. Hauber, A. & Gordon, J. D. Europe Equity Research Report (J. P. Morgan, 5 Feb 2010).
Cited by
Items 101–183 of 183
Pedersen, S. S., Donslund, A. S., Mikkelsen, J. H., Bakholm, O. S., Papp, F., Jensen, K. B., Gustafsson, M., & Skrydstrup, T. (2021) · Chemistry - A European Journal · doi:10.1002/chem.202005261 · Cited by 16
Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges
Allard, C., Cota, D., & Quarta, C. (2023) · Drugs · doi:10.1007/s40265-023-01982-6 · Cited by 17
Engineering of smart nanoconstructs for delivery of glucagon-like peptide-1 analogs
Eissa, N. G., Elsabahy, M., & Allam, A. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120317 · Cited by 17
Li, Y., Shao, M., Zheng, X., Kong, W., Zhang, J., & Gong, M. (2013) · Molecular Pharmaceutics · doi:10.1021/mp4001734 · Cited by 15
Hepatic function of glucagon-like peptide-1 and its based diabetes drugs
Feng, J. N., & Jin, T. (2024) · Medical Review · doi:10.1515/mr-2024-0018 · Cited by 18
“The non-covalent binding with the albumin molecule e ff ectively prevents its renal elimination, making its half-life approximately 13 h [42 – 44].”
BackgroundKaji, N., Takagi, Y., Matsuda, S., Takahashi, A., Fujio, S., & Asai, F. (2020) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12106 · Cited by 13
Gao, Z., Wei, Y., Ge, J., Liu, J., Qin, Y., Gong, F., & Ma, G. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c04010 · Cited by 15
Overcoming Cellular and Systemic Barriers to Design the Next Wave of Peptide Therapeutics
Hochman, J. H., Sawyer, T. K., & Duggal, R. (2021) · Methods in pharmacology and toxicology · doi:10.1007/978-1-0716-1250-7_10 · Cited by 12
Sustained Activation of CLR/RAMP Receptors by Gel-Forming Agonists
Chang, C. L., Cai, Z. P., & Hsu, S. Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113408 · Cited by 12
Wu, H., Lu, Z., Chen, R., Cai, Q., Wang, M., Zhang, L., & Zhu, Z. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1098032 · Cited by 15
Recent advances in drug delivery systems based on natural and synthetic polymes for treating obesity
Xiao, M., Wang, Z., Li, C., Zhang, K., Hou, Z., Sun, S., & Yang, L. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.129311 · Cited by 11
Jiang, N., Su, D., Chen, D., Huang, S., Tang, C., Jing, L., Yang, C.-Y., Zhou, Z., Yan, Z., & Han, J. D. J. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01049 · Cited by 10
A novel strategy to prepare the precursor peptide of liraglutide
Cheng, N., Yang, L., Dai, N., Hu, Z., Yang, F., Chen, R., Cheng, X., Zhou, J., Huang, Y., & Su, Z. (2017) · Process Biochemistry · doi:10.1016/j.procbio.2017.07.006 · Cited by 10
Tseng, Y., Chen, M., Lai, R., Oieni, F., Smyth, G., Anoopkumar‐Dukie, S., John, J. A. S., & Ekberg, J. A. K. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111819 · Cited by 9
de Gaetano, M. (2022) · Seminars in Immunology · doi:10.1016/j.smim.2022.101699 · Cited by 9
Nanotechnology and Diabetes Management: Recent Advances and Future Perspectives
Rashid, R., Naqash, A., Bader, G. N., & Sheikh, F. A. (2020) · Springer eBooks · doi:10.1007/978-981-15-5622-7_6 · Cited by 10
Park, S., & Kim, E. (2024) · Metabolites · doi:10.3390/metabo14090483 · Cited by 8
Aspartimide Formation and Its Prevention in Fmoc Chemistry Solid Phase Peptide Synthesis
Kong, M., van den Braak, T. J. H. P., & Neumann, K. (2025) · ChemBioChem · doi:10.1002/cbic.202500490 · Cited by 8
A Pharmacological Dose of Liraglutide Improves Mitochondrial Performance in Mouse Leydig Cells
Oliveira‐Lopes, B., Braga, P. C., Oliveira, P. F., Alves, M. G., & Bernardino, R. L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26188903 · Cited by 8
Murray, M., Schifano, F., Chiappini, S., Corkery, J., & Guirguis, A. (2025) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2025.12.015 · Cited by 14
Wolff, M., Schüler, A., Gast, K., Seckler, R., Evers, A., Pfeiffer‐Marek, S., Kurz, M. E., Nagel, N., Haack, T., Wagner, M., et al. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b01195 · Cited by 9
Ziebarth, J., Diedrich, C., Machado, C. S., & Mainardes, R. M. (2024) · Journal of Chromatography B · doi:10.1016/j.jchromb.2024.124015 · Cited by 8
Ghodge1, S. V., Biswas2, K., & Golosov3, A. A. (2022) · ACS symposium series · doi:10.1021/bk-2022-1417 · Cited by 9
Esteghamati, A., Zamanzadeh, M., Malek, M., Khaledi, M., MONAVVARI, A., Najafi, L., Banazadeh, Z., Malboosbaf, R., Aghili, R., Mahdikhah, S., et al. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01462-w · Cited by 9
Pan, Y., Shi, S., Lao, X., Zhang, J., Tan, S., Wu, Z., & Huang, J. (2016) · Peptides · doi:10.1016/j.peptides.2016.11.009 · Cited by 8
Potential role of IGF-1/GLP-1 signaling activation in intracerebral hemorrhage
Siddiqui, E. M., Mehan, S., Bhalla, S., & Shandilya, A. (2022) · Current Research in Neurobiology · doi:10.1016/j.crneur.2022.100055 · Cited by 6
Complex Peptide Injectables: Development and Challenges
Vinukonda, A., Rapolu, K., Jadi, R. K., & Devadasu, V. R. (2025) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-025-10710-5 · Cited by 8
“Its approval has provided patients with new treatment options for managing these challenging metabolic conditions (Drucker et al. 2010; Ladenheim 2015).”
Lou, W., Stimple, S. D., Desai, A. A., Makowski, E. K., Kalyoncu, S., Mogensen, J. E., Spang, L. T., Asgreen, D. J., Staby, A., Duus, K., et al. (2020) · Biotechnology and Bioengineering · doi:10.1002/bit.27610 · Cited by 6
Chan, D. C., Pang, J., & Watts, G. F. (2016) · Springer eBooks · doi:10.1007/978-3-319-11251-0_30 · Cited by 11
Wu, L., Ji, S., & Hu, T. (2015) · Molecular Pharmaceutics · doi:10.1021/mp500680p · Cited by 7
Current status of Liraglutide delivery systems for the management of type 2 diabetes mellitus
Chatterjee, R., Galave, V. S. B., & Jindal, A. B. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01965-y · Cited by 7
Advances in incretin therapies for targeting cardiovascular disease in diabetes
Roberts, T. D., Hutchinson, D. S., Wootten, D. L., Blasio, M. J. D., & Ritchie, R. H. (2025) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2025.03.007 · Cited by 7
Wu, Y., von Hauff, I., Jensen, N., Rossner, M. J., & Wehr, M. C. (2022) · Biosensors · doi:10.3390/bios13010048 · Cited by 6
Yousefpour, P., Varanko, A. K., Subrahmanyan, R., & Chilkoti, A. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000073 · Cited by 6
Ho, M. J., Liew, C. F., Tan, N. A. M. R., Morita, A., & Oon, H. H. B. (2026) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2026.2665732 · Cited by 7
“It was among the earliest GLP-1RAs to gain widespread use since approval by the FDA in 2010 [41].”
Supramolecular oral delivery technologies for polypeptide-based drugs
Chen, J., Liu, T., Wang, M., Lü, B., Bai, D., Shang, J., Chen, Y., & Zhang, J. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.02.045 · Cited by 5
Recent Trends in Peptide Drug Discovery and Development
Madge, H. Y. R., & Muttenthaler, M. (2024) · Royal Society of Chemistry eBooks · doi:10.1039/9781837674541-00023 · Cited by 6
Li, Y., Xu, W., Tang, L., Gong, M., & Zhang, J. (2011) · Peptides · doi:10.1016/j.peptides.2011.05.026 · Cited by 5
Nonogaki, K., & Suzuki, M. (2013) · ISRN Endocrinology · doi:10.1155/2013/184753 · Cited by 7
Zheng, X., Li, Y., Li, X., Tang, L., Xu, W., & Gong, M. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.05.021 · Cited by 5
Frimann, T. M., Ko, S. K., Harris, P., Bukrinski, J. T., & Peters, G. H. J. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2078409 · Cited by 6
Residence time distribution in flow reactors for solid phase synthesis
Pinzón-López, S., Hsu, W.-H., Ebert, D., Huei-Lin, M., Kraume, M., Seeberger, P. H., & Danglad-Flores, J. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.171495 · Cited by 3
Research Progress on Peptide Drugs for Type 2 Diabetes and the Possibility of Oral Administration
Yang, X., Lin, R., Feng, C., Kang, Q., Yu, P., Deng, Y., & Jin, Y. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16111353 · Cited by 6
Molecular engineering of designer diabetes therapeutics
DeWolf, E. L., Webber, B., & Webber, M. J. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114705 · Cited by 5
The long and the short of interferon-gamma–inducible protein 10 in hepatitis C virus infection
Gorrell, M. D., Zekry, A., McCaughan, G. W., Lloyd, A. R., Kowdley, K. V., McCaughan, G. W., & Trautwein, C. (2011) · Hepatology · doi:10.1002/hep.24600 · Cited by 4
Chan, D. C., Pang, J., & Watts, G. F. (2015) · Springer eBooks · doi:10.1007/978-3-319-12125-3_30-1 · Cited by 7
Huang, P., Meng, L., Tan, J., Gu, X., Huang, M., Huang, F., Ma, R., & Wang, J. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119136 · Cited by 4
Zhang, L., Li, X., Zhang, J., Wang, X., & Fu, Y. (2025) · Biomedical Chromatography · doi:10.1002/bmc.70118 · Cited by 3
Gel-forming antagonist provides a lasting effect on CGRP-induced vasodilation
Chang, C. L., Cai, Z. P., & Hsu, S. Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1040951 · Cited by 3
Chang, C. L., Cai, Z. P., & Hsu, S. Y. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003440 · Cited by 5
Structural Aspects of Gut Peptides with Therapeutic Potential for Type 2 Diabetes
Hewage, C. M., & Venneti, K. C. (2013) · ChemMedChem · doi:10.1002/cmdc.201200445 · Cited by 3
Kong, W., Fang, B., & Xing, W. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70301 · Cited by 2
“17 Nevertheless, existing RCTs are limited by small sample sizes and heterogeneous outcome measures.”
Novel Modified GLP-1 Derivatives with Prolonged Glucose-Lowering Ability In Vivo
Liu, Y., Wang, Q., Nie, D., Zhang, Y., Wang, Z., & Zhang, Y. (2019) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-019-09991-4 · Cited by 2
Metabolic resilience: liraglutide’s potential in alleviating depressive symptoms
Gammoh, O., Qnais, E. Y., Aljabali, A. A. A., Hatahet, T., & Alqudah, A. M. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10641-w · Cited by 2
“Liraglutide (also known commercially as Saxenda ® , Vic-toza ® , and Xultophy ® ) has transcended its original purpose as a GLP-1 receptor analog, initially developed for the treat-ment of type 2 diabetes mellitus and the prevention of diabetes-related cardiovascular complications [8–10].”
Cao, Z., Li, Y., Tang, L., Xu, W., Liu, C., Zhang, J., & Gong, M. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.01.010 · Cited by 2
Khroud, M., Song, Z., Shao, W., & Jin, T. (2019) · Obesity Medicine · doi:10.1016/j.obmed.2019.100153 · Cited by 2
Recombinant live biotherapeutics: A new frontier in peptide drug biosynthesis and precision delivery
Chawla, M., Bhange, O., & Das, B. (2025) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2025.12.002 · Cited by 1
Helal, M. M., Almosilhy, N. A., Abo‐elnour, D. E., Jaffal, R., Allam, E. G., Almosilhy, M. A., Batarseh, S. F., & Meshref, M. M. (2026) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2026.2627901 · Cited by 3
Cutting-edge nanotechnology in diabetes care: metamorphosing diagnostics and treatment strategies
Sarkhel, S., Shuvo, S. M., Sarkar, T., GHOSH, A., Kapat, P., & Biswas, R. (2026) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-026-00941-8 · Cited by 3
Saini, J. K., Narwal, S., Singh, J., Dhingra, A. K., Dushyant, Singh, G., & Grewal, N. (2026) · Protein and Peptide Letters · doi:10.2174/0109298665438727260217054757 · Cited by 1
Acute Contractile Effects of Glucagon-like-Peptide-1 Receptor Agonists in the Human Heart
Neumann, J., Kirchhefer, U., Hofmann, B., & Gergs, U. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18040447 · Cited by 1
“Animal studies: Liraglutide was designed starting with the protein sequence of GLP-1 and modified such that the binding to albumin was enhanced [40].”
Park, J.-H., Song, Y.-B., Kang, Y.-R., & Lee, B. (2026) · Food Science and Biotechnology · doi:10.1007/s10068-026-02166-0 · Cited by 1
A gel-forming α-MSH analog promotes lasting melanogenesis
Chang, C. L., Cai, Z. P., & Hsu, S. Y. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176008 · Cited by 2
A review on the use of adjunctive therapies in artificial pancreas systems
Furió-Novejarque, C., Díez, J.-L., & Bondía, J. (2024) · IFAC-PapersOnLine · doi:10.1016/j.ifacol.2024.11.053 · Cited by 2
Andreev-Andrievskiy, A. A., Александрович, М. М., Vannous, M., Fadeeva, O. V., Kazaishvili, Y. G., Куркин, Д. В., Zaslavskaya, K. Y., Beliy, P. A., Таганов, А. В., Rogozhina, E. A., et al. (2025) · Pharmacy & Pharmacology · doi:10.19163/2307-9266-2025-13-3-171-183 · Cited by 2
Estado actual del tratamiento farmacológico de la diabetes mellitus. Una aproximación práctica
Gracia, T. R., & Pascual, A. L. C. (2013) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(13)70691-7
Kanamarlapudi, V. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734616040.793572407
(2022) · ACS symposium series · doi:10.1021/bk-2022-1417.ix002
(2022) · ACS symposium series · doi:10.1021/bk-2022-1417.ot001
(2022) · ACS symposium series · doi:10.1021/bk-2022-1417.fw001
Optimization of Peptide Drug Exposures for Pharmacological Efficacy: DMPK Considerations
Duggal, R., & Hochman, J. H. (2022) · ACS symposium series · doi:10.1021/bk-2022-1417.ch010
Ghodge, S. V., Biswas, K., & Golosov, A. A. (2022) · ACS symposium series · doi:10.1021/bk-2022-1417.pr001
Efikasi Liraglutide Dalam Tatalaksana Obesitas Pada Pasien Dewasa Diabetik dan Non-Diabetik
Bramasta, A. A., & Novitasari, D. (2024) · Malahayati Nursing Journal · doi:10.33024/mnj.v6i2.12883
Furió-Novejarque, C. (2024) · RiuNet (Universitat Politècnica de València) · doi:10.4995/thesis/10251/202872
Food-Derived Bioactive Peptides as Potential Antimicrobial Agents: Challenges and Opportunities
Kasana, A., & Verma, V. (2025) · Springer eBooks · doi:10.1007/978-981-96-4379-0_8 · Cited by 1
Residence Time Distribution in Flow Reactors for Solid Phase SynthesisPreprint
Pinzón-López, S., Hsu, W.-H., Ebert, D., Huei-Lin, M., Kraume, M., Seeberger, P. H., & Danglad‐Flores, J. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5583415
Liquid-Phase Synthesis of Peptide Alcohol Assisted by a Hydrophobic Silica-Based Tag
Cheng, R., Qian, Y., Xu, Y., & Su, X. (2025) · Chinese Journal of Organic Chemistry · doi:10.6023/cjoc202503021
Peptides: fascinating, unique, and universal molecules with incredible potentials
Roy, R. K., Soren, K., Khan, D., Goswami, A., Shaw, R., Ghorui, M., Chakraborty, P., Biswas, R., & Bandopadhyay, R. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-15652-6.00007-2
Ziebarth, J., Babinski, T. P., Moreira, F. F., Tartari, A. P. S., Zago, A., Costa, S. P. D., Pinheiro, M. F., & Mainardes, R. M. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.153507
Kim, T., Seo, J., Kang, S., Kim, H. K., Lee, B., Lee, J., & Go, G. (2026) · Food Science and Biotechnology · doi:10.1007/s10068-026-02259-w
Sayed, N. A., Mohamed, N. A. L., Zohny, S. A. E., & Ali, A. B. H. (2026) · Microchemical Journal · doi:10.1016/j.microc.2026.120064
Metadata
- Authors
- Drucker, D. J., Dritselis, A., & Kirkpatrick, P.
- Affiliations
- Mount Sinai Hospital (CA)
- Venue
- Nature Reviews Drug Discovery
- Published
- 2010-04
- Volume
- 9
- Issue
- 4
- Pages
- 267-268
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W4245650535
- Cited by
- 181
- References
- 13
- Citations by year
- 2026: 11 · 2025: 19 · 2024: 13 · 2023: 12 · 2022: 21 · 2021: 9 · 2020: 10 · 2019: 11 · 2018: 8 · 2017: 8 · 2016: 6 · 2015: 8 · 2014: 11 · 2013: 12 · 2012: 6
- FWCI
- 8.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- liraglutide, GLP-1 receptor agonists, type 2 diabetes, glycemic control, FDA approval, injectable drugs
- MeSH terms
- Liraglutide, Adult, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, United States, United States Food and Drug Administration, Randomized Controlled Trials as Topic, Drug Approval, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.